esketamine
Articles tagged with “esketamine”
Esketamine Clinic Protocols: What Troche Patients Should Know
New guidance on esketamine clinical setup highlights why ketamine troches remain a flexible, accessible alternative for many treatment-resistant depression patients.
Ketamine Dropout Rates: The Case for Troche Optimization
New clinical data on NMDA antagonist side effects and dropout rates reveals why troche dosing flexibility may improve long-term treatment adherence.
Ketamine Dropout Rates: Why Delivery Format Changes Everything
New clinical data on NMDA antagonist side effects and dropout rates shows why ketamine troche delivery may offer a meaningful tolerability advantage.
Side Effects & Stopping Rates: What NMDA Data Means
New data on NMDA antagonist side effects and discontinuation rates has direct implications for ketamine troche patients managing treatment-resistant depression.
Ketamine Side Effects: What New Data Means for Troches
New research on NMDA antagonist side effects in treatment-resistant depression highlights why ketamine troches offer a distinct safety and tolerability profile.
NMDA Antagonist Side Effects: What Troche Users Need to Know
New clinical guidance on NMDA antagonist side effects and discontinuation rates has direct implications for ketamine troche patients. Here's what it means for your treatment.
Glutamate Pathway Treatments Reshape TRD Care in 2026
New research highlights glutamate-targeting treatments for TRD, including esketamine and ketamine troches. Here's what it means for your care plan.
NMDA Side Effects: What Troche Users Need to Know
New clinical data on NMDA receptor antagonist side effects and dropout rates—and what it means for ketamine troche dosing and monitoring routines.
Esketamine vs. Troches: What TRD Patients Should Know
A new clinical review on esketamine for TRD highlights access barriers and patient preferences — here's what it means for ketamine troche therapy.
Esketamine TRD Access Gaps Open Doors for Troches
New clinician data on esketamine for TRD reveals access barriers that make compounded ketamine troches a practical frontline option for many patients.
Glutamate Pathways Are Reshaping TRD Treatment
A 2026 review highlights how glutamate-targeting drugs like esketamine and ketamine troches are redefining treatment-resistant depression care.
Glutamate Pathway Treatments Reshape TRD Care
New research highlights glutamate-based treatments for treatment-resistant depression. Here's what it means for ketamine troche patients in 2026.
Compounded Ketamine vs. Brand-Name Spravato: Full Comparison
Compare compounded racemic ketamine (troches, nasal spray) with FDA-approved Spravato (esketamine) on efficacy, cost, FDA approval, access, and clinical suitability.
Ketamine Troches vs. Nasal Spray: Compounded and Brand-Name Options
Compare ketamine troches with compounded nasal spray and FDA-approved Spravato (esketamine). Understand the differences in molecule, bioavailability, cost, and access.
Contact Ketamine Troche
Send corrections, provider questions, or advertising inquiries.